EUVIMEDEUVIMED entdecken
Open Access

Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures

Katharina Wang iD, Laura Schober, Alessa Fischer iD, Nicole Bechmann, Julian Maurer, Lea Peischer, Astrid Reul, Constanze Hantel, Martin Reincke iD, Felix Beuschlein iD, Mercedes Robledo iD, Hermine Mohr und 15 weitere

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Katharina Wang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany. Hauptthemen laut MEDLINE: Cannabidiol, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: German Research Foundation, University Medicine Zurich, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Treatment options for advanced neuroendocrine tumors (NETs), pheochromocytomas and paragangliomas (PPGLs) are still limited. In recent years, antitumor effects of cannabinoids have been reported; however, there are only very limited data available in NETs or PPGLs.

Objective

Investigation of the effects of cannabidiol (CBD) on patient-derived human NET/PPGL primary cultures and on NET/PPGL cell lines.

Methods

We established primary cultures derived from 46 different patients with PPGLs (n = 35) or NETs (n = 11) who underwent tumor resection at 2 centers. Treatment of patient primary cultures with clinically relevant doses (5 µM) and slightly higher doses (10 µM) of CBD was performed.

Results

We found opposing effects of 5 µM CBD: significant antitumor effects in 5/35 (14%) and significant tumor-promoting effects in 6/35 (17%) of PPGL primary cultures. In terms of antitumor effects, cluster 2-related PPGLs showed significantly stronger responsivity to CBD compared to cluster 1-related PPGLs (P = .042). Of the cluster 2-related tumors, NF1 PPGLs showed the strongest responsivity (4/5 PPGL primary cultures with a significant decrease in cell viability were NF1-mutated). We also found opposing effects of 10 µM CBD in PPGLs and NETs: significant antitumor effects in 9/33 of PPGL (27%) and 3/11 of NET (27%) primary cultures and significant tumor-promoting effects in 6/33 of PPGL (18%) and 2/11 of NET (18%) primary cultures.

Conclusion

We suggest a potential novel treatment option for some NETs/PPGLs but also provide evidence for caution when applying cannabinoids as supportive therapy for pain or appetite management to cancer patients and possibly as health supplements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolParagangliomaPheochromocytomaNeuroendocrine TumorsAdrenal Gland NeoplasmsHumansFemaleMaleMiddle AgedAdultTumor Cells, CulturedAgedYoung AdultCell Line, TumorAntineoplastic AgentsPrimary Cell Culture

Stichwörter der Autor:innen

CBDcannabidiolcannabinoidsneuroendocrine tumorpheochromocytoma and paraganglioma

Substanzen

CannabidiolAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich and University of Zurich, CH-8091 Zurich, Switzerland.
  • Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany.
  • Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden, 01307 Dresden, Germany.
  • The LOOP Zurich-Medical Research Center, 8044 Zurich, Switzerland.
  • Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center, 28029 Madrid, Spain.

ORCID-Profile: Katharina Wang, Alessa Fischer, Martin Reincke, Felix Beuschlein, Mercedes Robledo, Katharina Schilbach, Kuno Lehmann, Karel Pacak, Svenja Nölting

Förderung

  • German Research Foundation
  • University Medicine Zurich
  • NIH

Zitieren

APA

Wang, K., Schober, L., Fischer, A., Bechmann, N., Maurer, J., Peischer, L., Reul, A., Hantel, C., Reincke, M., Beuschlein, F., Robledo, M., Mohr, H., Pellegata, N. S., Schilbach, K., Knösel, T., Ilmer, M., Angele, M., Kroiss, M., Maccio, U., …, & Nölting, S. (2024). Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae241

Vancouver

Wang K, Schober L, Fischer A, Bechmann N, Maurer J, Peischer L, et al. Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae241

BibTeX
@article{Wang2024,
  author = {Wang, Katharina and Schober, Laura and Fischer, Alessa and Bechmann, Nicole and Maurer, Julian and Peischer, Lea and Reul, Astrid and Hantel, Constanze and Reincke, Martin and Beuschlein, Felix and Robledo, Mercedes and Mohr, Hermine and Pellegata, Natalia S and Schilbach, Katharina and Knösel, Thomas and Ilmer, Matthias and Angele, Martin and Kroiss, Matthias and Maccio, Umberto and Broglie-Däppen, Martina and Vetter, Diana and Lehmann, Kuno and Pacak, Karel and Grossman, Ashley B and Auernhammer, Christoph J and Zitzmann, Kathrin and Nölting, Svenja},
  title = {Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae241}
}
Kostenlos starten →